(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.54%) $78.90
(-1.23%) $2.17
(0.26%) $2 337.20
(0.20%) $27.67
(0.49%) $969.60
(-0.01%) $0.928
(-0.06%) $10.82
(-0.03%) $0.796
(-0.02%) $91.33
2 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
1.06% ¥ 1 627.00
Live Chart Being Loaded With Signals
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally...
Stats | |
---|---|
Tagesvolumen | 400.00 |
Durchschnittsvolumen | 4 322.00 |
Marktkapitalisierung | 5.87B |
EPS | ¥0 ( 2024-01-30 ) |
Nächstes Ertragsdatum | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥50.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -24.41 |
ATR14 | ¥0 (0.00%) |
Nippon Chemiphar Co., Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Nippon Chemiphar Co., Finanzdaten
Annual | 2022 |
Umsatz: | ¥31.56B |
Bruttogewinn: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Umsatz: | ¥31.56B |
Bruttogewinn: | ¥8.19B (25.94 %) |
EPS: | ¥93.92 |
FY | 2022 |
Umsatz: | ¥32.51B |
Bruttogewinn: | ¥9.07B (27.91 %) |
EPS: | ¥194.33 |
FY | 2021 |
Umsatz: | ¥31.54B |
Bruttogewinn: | ¥11.44B (36.28 %) |
EPS: | ¥137.75 |
Financial Reports:
No articles found.
Nippon Chemiphar Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥50.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥30.00 | 2008-03-26 |
Last Dividend | ¥50.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | ¥1 040.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.8 | -- |
Div. Sustainability Score | 5.79 | |
Div.Growth Potential Score | 1.781 | |
Div. Directional Score | 3.78 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7956.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7187.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
6432.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
5411.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4433.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
3612.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
2818.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
1446.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9740.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
8795.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.00787 | 1.500 | -0.157 | -0.236 | [0 - 0.5] |
returnOnAssetsTTM | -0.00473 | 1.200 | -0.158 | -0.189 | [0 - 0.3] |
returnOnEquityTTM | -0.0130 | 1.500 | -1.255 | -1.883 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.43 | 0.800 | 2.86 | 2.29 | [1 - 3] |
quickRatioTTM | 1.563 | 0.800 | 5.51 | 4.41 | [0.8 - 2.5] |
cashRatioTTM | 0.747 | 1.500 | 6.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.344 | -1.500 | 4.27 | -6.41 | [0 - 0.6] |
interestCoverageTTM | -3.58 | 1.000 | -2.44 | -2.44 | [3 - 30] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.934 | -1.500 | 6.26 | -9.40 | [0 - 2.5] |
grossProfitMarginTTM | 0.251 | 1.000 | 9.15 | 9.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0153 | 1.000 | -2.31 | -2.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.164 | 1.000 | -0.199 | -0.199 | [0.2 - 2] |
assetTurnoverTTM | 0.601 | 0.800 | 9.33 | 7.46 | [0.5 - 2] |
Total Score | 5.79 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -24.11 | 1.000 | -2.54 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0130 | 2.50 | -0.807 | -1.883 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 796.41 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.249 | 1.500 | -4.99 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0939 | 1.000 | -0.153 | 0 | [0.1 - 0.5] |
Total Score | 1.781 |
Nippon Chemiphar Co.,
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.